Gruenberger B et al. – Colorectal cancer pts with liver metastases have high response rates with neoadjuvant oxaliplatin-based chemotherapy without increased perioperative morbidity; chemotherapy response can lead to long-term recurrence-free survival; neoadjuvant chemotherapy may identify the best candidates for potentially curative treatment Methods
Prospective study of whether neoadjuvant chemotherapy reduces recurrence risk after potentially curative liver resection
Administration of neoadjuvant XELOX or FOLFOX4 for 6 cycles (3 mo) to 50 pts with resectable liver metastases; then complete resection of liver metastases
Assessments of response rate, postoperative morbidity, and recurrence-free survival
Results
Objective response in 72% of pts, including 2 complete responses
Chemotherapy was well tolerated
Most adverse events were mild to moderate (grade 1/2)
Potentially curative R0 resection performed in all pts; postoperative complications in 12% of pts
Median recurrence-free survival significantly influenced by tumor response: 24.7 mo for responding pts, 8.2 mo for stable disease pts, 3 mo in progressive disease pts
See all
